Mumbai, Feb. 13 -- Shilpa Medicare (SML) has entered into a binding agreement with NXI

Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE). Under the terms of the strategic collaboration, SML will support both development - including first-in-human clinical studies - as well as long-term commercial supply

with GMP manufacturing.

Published by HT Digital Content Services with permission from Capital Market....